EUS Needle Market Size and Shares and Trend Analysis | Global | 2026-2032 | Includes: Fine Needle Aspiration and Fine Needle Biopsy

The global endoscopic ultrasound needle market was valued at nearly $374 million in 2025. The market is expected to grow at a compound annual growth rate of 3.9 percent to reach over $490 million by 2032.

This report covers endoscopic ultrasound needles segmented by device type into fine-needle aspiration and fine-needle biopsy. It quantifies unit sales, average selling prices, market values, growth rates, and company shares, and it analyzes market drivers and limiters, recent mergers and acquisitions, and technology trends. It provides historical data to 2022 and forecasts to 2032.

The scope reflects how hospitals and endoscopy centers evaluate EUS-guided tissue acquisition as imaging and visualization improve, while pricing trends, training access, and regulatory requirements shape adoption across regions.

Market Overview

Endoscopic ultrasound needles are used for EUS-guided tissue acquisition across the gastrointestinal tract and adjacent organs. They enable cytology and histology sampling of lesions in the pancreas, biliary system, subepithelial masses, and lymph nodes. As ultrasound image quality improves and clinician familiarity grows, EUS-guided sampling plays a larger role in diagnosis and staging.

In recent years, disposable EUS needle prices have trended downward, which supported a steady rise in procedure volumes. The pricing environment is anticipated to stabilize, with modest additional declines over the forecast horizon. Affordability expands access for hospitals and ambulatory endoscopy centers, which increases the installed user base and supports higher total revenues despite tighter margins. Sustained gains in unit sales are expected to underpin continued market growth.

The market mix between fine-needle aspiration and fine-needle biopsy continues to evolve. EUS-FNA has a long record for cytology. EUS-FNB has expanded due to devices designed to obtain core tissue for histologic assessment. As pathology needs shift toward ancillary testing and as clinical guidelines emphasize accurate subtyping, FNB adoption is increasing in many centers. This mix affects average selling prices and procedure economics, since FNB devices typically command a premium over FNA.

Overall, EUS needle adoption reflects a convergence of diagnostic accuracy, workflow efficiency, and cost control, supported by improved imaging, more consistent tissue yields, and growing clinician comfort with EUS-guided techniques.

Market Drivers

Increased diagnostic capabilities

New diagnostic approaches that include ultrasound endoscopy are strengthening detection of gastrointestinal abnormalities and disease. Improvements in imaging and visualization, including high-definition ultrasound and enhanced endoscope optics, have increased targeting precision and sampling confidence. As diagnostic accuracy improves, biopsy volumes are expected to rise, which drives greater demand for EUS needles and supports market expansion.

Advancements in imaging and guidance

Incremental advances in image quality and ergonomic scope control are improving lesion localization and needle trajectory planning. Better visualization facilitates sampling of difficult targets and reduces the number of passes needed to obtain diagnostic material. These gains support higher first-pass success and shorter procedure time, which encourages broader use of EUS-guided tissue acquisition.

Rising incidence of gastrointestinal disorders

Global prevalence of conditions that require tissue confirmation, including pancreatic masses, cysts, biliary strictures, and subepithelial lesions, continues to rise with aging populations and improved detection. As patient volumes increase, utilization of FNA and FNB grows accordingly. This demand increase, combined with more centers offering EUS services, supports sustained unit growth through the forecast period.

Price accessibility and broader adoption

A multiyear decline in disposable needle prices made EUS needles more accessible across a wider range of care settings. While manufacturers faced margin compression, expanding customer bases helped offset the impact. With pricing expected to stabilize and only modest reductions projected, unit growth will remain the main driver of market value.

Market Limiters

Technical challenges and training needs

Sampling small or hard-to-reach lesions can be difficult. Certain targets require precise angulation, stable scope position, and consistent suction and stylet techniques. Effective use of EUS often depends on specialized training, which can limit adoption in centers with fewer advanced endosonographers. Training access and proctoring availability remain important constraints in some regions.

Competition among tissue-acquisition techniques

Preference patterns between FNA and FNB can shift based on pathology requirements, device cost, and clinician familiarity. In addition, alternative biopsy modalities outside EUS in select indications can divert cases. These factors influence product mix and apply pressure on average selling prices, which moderates overall market value growth even as total procedures rise.

Regulatory and compliance requirements

Strict standards for device design, manufacturing, and clinical use can lengthen development timelines and raise operating costs. Regulatory compliance is necessary but can act as a barrier to market entry and slow the pace of product iteration. In cost-sensitive markets, longer approval cycles and procurement rules can delay upgrades and restrain ASP expansion.

Market Coverage and Data Scope

Quantitative coverage

Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.

Qualitative coverage

Growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews that shape demand for EUS needles.

Time frame

Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.

Data sources

Primary interviews with industry leaders, government physician data, regulatory data, hospital private data, import and export data, and the iData Research internal database.

Method note

Revenue is modeled from units multiplied by ASP, validated with procedure and utilization inputs, and cross-checked against adoption and replacement assumptions for FNA and FNB.

Care settings

Hospitals, specialty clinics, and ambulatory endoscopy centers.

Markets Covered and Segmentation

EUS Needle Market

• By device type: fine-needle aspiration, fine-needle biopsy.

Competitive Analysis

Boston Scientific held the leading position in the EUS needle market in 2025. The company has a strong presence through its Acquire fine-needle biopsy devices and Expect fine-needle aspiration product line, which together secure a significant share. The installed base, distribution reach, and portfolio depth support its leadership across many regions.

Cook Medical ranked as the second-largest competitor. The company maintains a strong position with its EchoTip Ultra Endoscopic Ultrasound Needle and participates in the reusable segment, which broadens its presence across different purchasing models and regions.

Medtronic has a notable share supported by its reusable offering and its SharkCore fine-needle biopsy system and Beacon fine-needle aspiration system. These lines contribute meaningfully to the company's EUS needle sales and provide coverage across cytology and histology use cases.

The market remains moderately concentrated across global leaders with broad portfolios and regional distributors that address local price points and procurement practices.

Technology and Practice Trends

EUS-FNB adoption is increasing where histology and ancillary testing are prioritized, which can raise ASPs relative to FNA and improve diagnostic workflow for certain lesions.

EUS-FNA remains widely used for cytology in a broad range of targets, with continued optimization of tip designs, bevel geometry, and stylet options.

Imaging improvements in high-definition ultrasound and scope articulation support better targeting and reduce the number of passes needed for diagnosis.

Single-use device preference continues to expand as infection prevention and streamlined workflow reduce reliance on reprocessing infrastructure.

Tissue acquisition standardization through procedural checklists and training modules helps improve yield consistency and reduces variability between centers.

Procurement strategies balance price stabilization with reliability and supply continuity, favoring vendors that can support multiple device sizes and quick replenishment.

Geography

This edition provides global coverage, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Why This Report

Where is the largest and fastest growing opportunity within EUS needles and how will the mix between FNA and FNB evolve through the forecast period.

How do pricing trends and procedure volumes interact to drive market value, and what is the outlook for price stabilization versus further reductions.

Which technology and practice trends will shape adoption, including imaging improvements, needle design updates, and single-use preference.

How do leading competitors position their portfolios across regions, and what is the likely impact of procurement and regulatory environments on share and pricing.

What training, workflow, and pathology requirements affect device selection, including yield targets and the need for core tissue to support diagnostic confidence.

How should commercial teams plan for growth in hospitals and ambulatory centers, and where are the key risks to value, including technical challenges, regulatory timelines, and mix shifts between FNA and FNB.

The Global Endoscopic Ultrasound Needle Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and price benchmarking. Use it to quantify demand by device type, plan portfolio strategy, set pricing and contracting targets, and prioritize training and support programs that improve diagnostic yield.